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Abstract
Background/Aim. Most infections caused by influenza A
(H1N1) 2009 virus are presented by mild respiratory
symptoms. However, some patients required admission to
the intensive care unit (ICU). In this article we aimed to de-
scribe the clinical and laboratory characteristics of the pa-
tients with influenza A (H1N1) 2009, antiviral therapy use,
the disease outcome and risk factors associated with the se-
vere disease. Methods. The patients with the signs and
simptoms of novel influenza A (H1N1) 2009, admitted to
the Clinic for Infectious Disease in Novi Sad, were evalu-
ated. The study included 293 patients hospitalized between
October 2009 and February 2010. Basic demographic data,
underlying medical conditions, clinical signs and symptoms,
duration of the disease before the admission, laboratory
tests, radiographic findings, treatment, and the final out-
come (survived, died) were all noted. Factors associated
with severe disease requiring ICU admission were deter-
mined by comparing the ICU cases with control groups of
the patients admitted to the hospital but not to ICU. Re-
sults. The average age of the patients was 32.72 years. A
total of 114 (38.9%) of the patients had an underlying medi-
cal condition. Asthma and chronic obstructive pulmonary
disease were present in 44 (15.01%) of the patients, chronic
cardiovascular diseases in 28 (9.56%), diabetes mellitus in 16
(5.46%), malignity in 15 (4.44%) of the patients and 11
(3.75%) of the patients were pregnant. Fever was registered
in 282 (96.24%), myalgias in 119 (40.61%), headache in 48
(16.38%), cough in 240 (81.91%), sore throat in 25 (8.53%),
runny nose and sneezing in 17 (5.8%) and dyspnea in 110
(37.54%) of the patients. A total of 192 (65.53%) had ra-
diological findings that were consistent with pneumonia. A
total of 154 (56.61%) of the patients received antiviral ther-
apy within 48 h. A total of 280 (96.24%) patients were dis-
charged and 13 (4.44%) were transferred to ICU. Fatal out-
come was noticed in 2/13 (15.3%) ICU treated patients and
11/13 (84.7%) patients survived. The median time from the
onset of illness to the initiation of antiviral treatment was
7.1 days for the patients admitted to ICU and 3.2 days for
non-ICU patients (p < 0.05). Low blood oxygen saturation
(SaO2  92%) was more common in ICU admitted patients,
10/13 (76,92%), compared to 28/280 (10%) non-ICU ad-
mitted ones (p < 0.01). Serum C-reactive protein (CRP) lev-
els >  200 mg/L were noticed in 9/13 (69.23%) patients
admitted to ICU and 85/280 (30.35%) patients who were
not (p < 0.05).  Conclusion.  Most novel influenza A
(H1N1) 2009 infections presented mild respiratory disease.
Prompt antiviral therapy in patients with A (H1N1) virus in-
fection seem to be the best approach to avoid serious form
of the disease. Special attention should be payed to patients
having low level of peripheral oxygen saturation and raised
CRP serum level.
Key words:
influenza a virus, h1n1 subtype; serbia; diagnostic
techniques and procedures; drug therapy; comorbidity;
pneumonia; prognosis.
Apstrakt
Uvod/Cilj. Infekcije uzrokovane virusom gripa A (H1N1)
u veýini sluÿajeva manifestuju u blagom respiratornom sim-
ptomatologijom. Ipak, neki bolesnici zahtevaju hospitaliza-
ciju u jedinicama intenzivne nege (intensive care units – ICU).
Cilj rada bio je prikazivanje kliniÿkih i laboratorijskih karak-
teristika bolesnika sa gripom A (H1N1) 2009, primenjene
antivirusne terapije, ishoda bolesti i faktora rizika od razvoja
teškog oblika bolesti. Metode. Studijom su bili obuhvaýeniStrana 156 VOJNOSANITETSKI PREGLED Volumen 70, Broj 2
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bolesnici sa znacima i simptomima pandemijskog gripa A
(H1N1), hospitalizovani u Klinici za infektivne bolesti u
Novom Sadu. Studijom je bilo obuhvaýeno 293 bolesnika
hospitalizovanih u periodu od oktobra 2009. do februara
2010. godine. Analizirani su osnovni demografski podaci,
osnovne bolesti, znaci i simptomi gripa, trajanje simptoma
do hospitalizacije, laboratorijske analize, radiografski nalaz,
terapija i ishod bolesti (preživeli, umrli). Definisanje faktora
rizika od težeg oblika bolesti vršeno je uporeĀivanjem kara-
kteristika ICU bolesnika sa karakteristikama bolesnika koji
nisu zahtevali hospitalizaciju u ICU. Rezultati.  Proseÿna
starost bolesnika bila je 32,72 godine.  Osnovne bolesti
imalo je 114 (38,9%) bolesnika. Astma i hroniÿna opstrukti-
vna bolest pluýa registrovana je kod 44 (15,01%) bolesnika,
hroniÿna kardiovaskularna oboljenja imalo je 28 (9,56%),
šeýernu bolest 16 (5,46%), malignitet 15 (4,44%) bolesnika,
a 11 (3,75%) bolesnika bile su trudnice. Povišena tempera-
tura registrovana je kod 282 (96,24%), bolovi u mišiýima
kod 119 (40,61%), glavobolja kod  48 (16,38%), kašalj kod
240 (81,91%), gušobolja kod 25 (8,53%), kijavica kod 17
(5,8%) i dispnea kod 110 (37,54%) bolesnika. Radiološki ve-
rifikovanu pneumoniju imalo je 192 (65,53%) bolesnika.
Antivirusna terapija kod 154 (56,61%) bolesnika primenjena
je u prvih 48 ÿasova bolesti. Sa klinike je otpušteno  280
(96,24%) bolesnika, a 13 (4,44%) bolesnika je premešeteno
u ICU. Smrtni ishod zabeležen je kod 2/13 (15,3%) boles-
nika leÿenih u ICU, dok je 11/13 (84,7%) preživelo. Prose-
ÿno vreme od pojave simptoma do primene antivirusne te-
rapije iznosilo je 7,1 dana za bolesnike leÿene u ICU, a 3,2
dana za bolesnike koji nisu bili hospitalizovani u ICU
(p < 0,05). Hipoksemija sa saturacijom kiseonika SaO2 
92% registrovana je kod 10/13 (76,92%) bolesnika leÿenih u
ICU, i kod 28/280 (10%) koji nisu premešteni u ICU
(p < 0,01). Vrednosti C-reaktivnog proteina (CRP) u serumu
> 200 mg/L zabeležena su kod 9/13 (69,23%) bolesnika u
ICU i kod 85/280 (30,35%) bolesnika bez transfera u ICU
(p < 0,05). Zakljuÿak. Novi grip se ispoljava uglavnom kao
blago respiratorno oboljenje. Rana primena antivirusne te-
rapije može spreÿiti razvoj težih formi oboljenja. Posebnu
pažnju treba obratiti na bolesnike sa hipoksemijom i poras-
tom vrednosti CRP u serumu.
Kljuÿne reÿi:
grip a virus, podtip h1n1; srbija; dijagnostiÿke tehnike i
procedure; leÿenje lekovima; komorbiditet;
pneumonija; prognoza.
Introduction
During the spring of 2009, a novel influenza A (H1N1)
virus of swine origin caused human infection and acute res-
piratory illness in Mexico 
1, 2. After initially spreading among
persons in the United States and Canada the virus spread
globally, resulting in the first influenza pandemic since 1968
with circulation outside the usual influenza season in the
Northern Hemisphere 
3, 4. By March 2010, almost all coun-
tries had reported cases, and more than 17,700 deaths among
laboratory-confirmed cases had been reported to the World
Health Organization (WHO) 
5.
Compared with seasonal influenza, the number of hos-
pitalizations, admission to intensive care units (ICU), and in-
vasive life support were disproportionately high among chil-
dren and young adults, whereas underlying medical condi-
tions, especially pregnancy, immunosuppression, obesity,
diabetes, cardiovascular and pulmonary disease were identi-
fied as risk factors for hospitalization of patients with pan-
demic influenza A (H1N1) 2009 
6–10. Frequently reported
complications have included pneumonia, bacterial coinfec-
tion and exacerbation of underlying medical conditions 
11–13.
The first case of pandemic influenza A (H1N1) in Vo-
jvodina was registered on June 24, 2009. At the end of Octo-
ber 2009, the mandatory outbreak investigation of acute res-
piratory illness detected new cases of pandemic influenza A
(H1N1) among students who had returned from school-
organised trips to Prague, Bratislava and Vienna. This was
considered the beginning of pandemic influenza in the
Autonomous Province of Vojvodina 
14, 15.
Although most patients presented mild and self-limited
symptoms with no sign of pulmonary involvement, some pa-
tients required admission to an ICU and received maximal
life support measures. Therefore, the information on the
clinical spectrum and risk factors for severe form of the dis-
ease, treatment and outcome of patients with pandemic influ-
enza A (H1N1) 2009 is still collected 
8, 16–18.
The aim of the study was to describe clinical and labo-
ratory characteristics of the patients with pandemic influenza
A (H1N1) 2009, antiviral therapy use, disease outcome and
risk factors associated with severe disease requiring admis-
sion to intensive care unit (ICU).
Methods
We retrospectively studied 293 patients with confirmed
or suspected novel influenza A (H1N1) 2009 hospitalized in
the Clinic for Infectious Diseases,  Clinical Center of Vo-
jvodina, between October 2009 and February 2010. We clas-
sified patients according to case definitions (confirmed or
suspected) developed by the WHO, Centers for Disease
Control and Prevention 
19, 20. A suspected case was defined
as an influenza-like illness (temperature  37.5°C and at least
one of the following symptoms: sore throat, cough, rhinor-
rhea or nasal congestion) and either a history of travel to a
country where infection had been reported in the previous 7
days or an epidemiologic link to a person with confirmed or
suspected infection in the previous 7 days. A confirmed case
was defined by a positive result of a real-time polymerase-
chain-reaction (RT-PCR) to identify the virus A (H1N1)
from nasopharyngeal swabs of the patients.
Our research was conducted based on available medical
records of 293 patients hospitalized between October 2009
and February 2010 in the Clinic for Infectious Disease in
Novi Sad. Basic demographic data, underlying medical con-
ditions, duration of the disease before the admission, clinical
signs and symptoms, laboratory tests, radiographic findings,
treatment, and the final outcome (survived, died) were allVolumen 70, Broj 2 VOJNOSANITETSKI PREGLED Strana 157
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noted. Factors associated with severe disease requiring ICU
admission were determined by comparing ICU patients with
control groups patients who were admitted to hospital but not
to an ICU.
Indications for hospital admission included radio-
graphic findings that were consistent with pneumonia, exac-
erbation of underlying medical condition, especially asthma
or chronic obstructive pulmonary disease, hypoxemia, he-
modynamic instability and dysfunction of other organs.
Critically ill patients with low blood oxygen saturation
(SaO2  92%) and with hemodynamic instability with the
need for vasopressors were transferred to ICU.
Laboratory analyses were performed in the laboratory
of the Clinical Centre of Vojvodina for all the patients in-
cluding  complete blood count, C-reactive protein (CRP),
urea, creatinine, alanine aminotransferasae (ALT), gamma-
glutamyl transpeptidase (GGT), creatine kinase (CK), lactate
dehydrogenase (LDH) and gas analysis.
Chest radiography were performed at the Institute of
Radiology, Clinical Center of Vojvodina. The diagnosis of
influenza A (H1N1) was confirmed by RT-PCR from naso-
pharyngeal swabs of the hospitalized patients. The test was
performed in a reference laboratory in the Institute of Immu-
nology and Virology “Torlak” Belgrade.
Diagnosis of pneumonia was based on clinical data and
radiographic infiltrates in the lung parenchyma. The diagno-
sis of acute respiratory distress syndrome (ARDS) was based
on clinical findings consistent with acute respiratory infec-
tion, massive bilateral lung infiltrates on chest radiography,
the absence of heart failure and low level of oxygen satura-
tion (Sa02 < 92%).
The results were presented as numbers and percentages.
The Fisher’s exact test was used to compare proportions for
categorical variables. For continuous variables, Student’s t-
test and Ȥ
2 test to assess the significance in differences be-
tween the groups were used. A probability level of p < 0.05
was considered statistically significant.
Results
The age of the hospitalized patients in our study ranged
from 2 to 84 years, the average age was 32.72 years. Totally
245 (83.6 %) patients were less than 50 years of age, and 61
(20.7%) were patients under the age of 19 years (Table 1).
Both genders were equally represented, 152 (51.88%) of the
patients were males and 141 (48.12%) were females.
Table 1
The age of 293 hospitalized patients with a novel influenza A
(H1N1)
Patients Age (years) n (%)
2–9 13 (4.3)
10–19 48 (16.4)
20–29 75 (25.6)
30–39 60 (20.5)
40–49 49 (16.8)
50–59 28 (9.6)
  60 20 (6.8)
Most patients had clinical symptoms and signs of gen-
eral infectious syndrome characteristic for influenza (Figure
1). Fever  38°C was registered in 282 (96.24%), myalgias
in 119 (40.61%) and headache in 48 (16.38%) of the pa-
tients. Most patients manifested more or less pronounced
symptoms and signs of the respiratory tract: cough was reg-
istered in 240 (81.91%), sore throat in 25 (8.53%), runny
nose and sneezing in 17 (5.8%) of the patients, while dysp-
nea was registered in 110 (37.54%) of the patients. Symp-
toms of gastrointestinal tract were recorded in less than ¼ of
the patients (24.2%).
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Fig. 1 – The signs and symptoms of a novel influenza A
(H1N1) in hospitalized patients
The average time from the onset of illness to hospital
admission in our series of patients was 3.7 days (range from
6 hours to 16 days). A total of 116 (39.59%) of them were
admitted within 48 hours, 172 (58.7%) within 3 days, 92
(31.4%) were admitted 4–7 days upon occurrence of first
symptoms, while 29 (9.9%) patients were hospitalized in the
second week (Table 2).
Table 2
The time from the onset of influenza A (H1N1) to hospital
admission in 293 patients
Patients The time (days) n (%)
1–3 172 (58.7)
4–7 92 (31.4)
> 7 29  (9.9)
A total of 114 (38.9%) patients had an underlying
medical condition on admission. Asthma and chronic ob-
structive pulmonary disease (COPD) were present in 44
(15.01%) of the patients, chronic cardiovascular diseases in
28 (9.56%), diabetes mellitus in 16 (5.46%), malignity in 15
(4.44%) of the patients and 11 (3.75%) of the patients were
pregnant (Figure 2).
Laboratory data on admission in our series of patients
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had leukopenia while leukocytosis was noted in 39 (19.31%)
of the patients. Thrombocytopenia was registered only in one
case, as a part of pancytopenia after chemotherapy in a pa-
tient with leukemia. Elevated serum enzymes were found in
less than ½ of the patients. ALT was elevated in 41 (14%) of
the patients, GGT in 10 (3.41%), LDH in 24 (8.15%) and
CK in 65 (22.18%) of the patients. Elevated CRP levels (> 5
mg/L) was noticed in 271 (92.49%) of the patients (median
133, range 7–312 mg/L) and CRP levels > 200 mg/L was
noticed in 94 (32.08%) of the patients.
Novel influenza A (H1N1) infection was confirmed in
19 (4.06%) patients by the real-time PCR test for identifica-
tion of influenza A (H1N1) virus.
A total of 292 patients underwent chest radiography on
admission and 192 (65.53%) had findings that were consis-
tent with pneumonia. Hypoxemia with the saturation of
SaO2  92% was noticed in 28 (9.5%) of the patients. ARDS
developed in one (2.93% ) patient.
Antiviral therapy was prescribed in 278 (94.88%) of
the patients after admission to the Clinic. All the patients re-
ceived oseltamivir. Totally 274 (93.5%) of the patients re-
ceived antibiotics. Commonly used antibiotics included
ceftriaxone, azithromycin and ciprofloxacin. The median
time from the onset of illness to the initiation of antiviral
therapy was 3.2 days (range, 1–12 days). A total of 154
(56.61%) patients received antiviral therapy within 48 h and
172 (76.1%) of the patients received antiviral therapy within
72 h after the onset of symptoms.
The outcome of illness among our patients was favor-
able in most cases. A total of 280 (96.24%) patients were
discharged and 13 (4.44%) were transferred to ICU. Fatal
outcome was noticed in 2/13 (15.3%) patients treated in the
ICU and 11/13 (84.7%) patients survived.
The median age of patients admitted to ICU was 28
years (range 6–52 yars). A total of 6 (46.15%) ICU patients
had an underlying medical condition on admission. There
was no significant difference in the prevalence of back-
ground medical conditions among the patients required ICU
hospitalization and those who did not. The median tempera-
ture and the duration of fever were similar for both hospital-
ized groups (Table 4).
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Fig. 2 – Underlying medical condition in hospitalized patients
Table 3
Laboratory data in 293 hospitalized patients with influenza
A (H1N1)
Patients Variables n (% )
WBC ! 10 u 10
9/mL
3 39 (19.31)
WBC  4.0 u 10
9
/mL
3
67 (22.87)
Lymphopenia 108 (36.86)
Lymphocytosis 42 (14.30)
Neutropenia 65 (22.18)
CRP ! 5 mg/L 271 (92.49)
CRP > 200 mg/L 94 (32.08)
Fibrinogen ! 4 g/L 62 (21.16)
Increased ALT 41 (14.0)
Increased GGT 10 (3.41)
Increased CPK 65 (22.18)
Increased LDH 24 (8.15)
WBC – white blood cells, CRP – C reactive protein;  ALT – alanine
aminotransferase; CPK – creatine phosphokinase; GGT – gamma-glutamyl
transpeptidase; LDH – lactate dehydrogenase
Table 4
Comparison between variables of ICU and non-ICU patients
Patients parameters Non-ICU
(n = 280)
ICU
(n = 13)
p
Age, median
Comorbidity, n (%)
32 28 > 0.05
asthma / COPD
chronic cardiovascular diseases
malignity
41 (14.64)
26 (9.29)
14 ( 5.0)
3 (23.07)
2 (15.38)
1 (7.69)
> 0.05
> 0.05
> 0.05
Temperature (°C) , median 38.1 37.9 > 0.05
Duration of fever (days), median 3.3 5.1 > 0.05
Saturation SaO2  92%, n (%) 28 (10) 10 (76.92) < 0.01
WBC (u10
9/mL
3), median 8.9 12.6 > 0.05
PMN (%), median 76 83 > 0.05
LYM (%), median 13 8 > 0.05
CRP > 200 mg/L, n (%) 85 (30.35) 9 (69.23%) < 0.05
CRP (mg/L), median 93 (7–282) 198 (66–312) < 0.01
Infiltrate on chest radiographɾ, n (%) 192 (68.57) 13 (100) > 0.05
Time from the onset of illness to the initiation
of antiviral therapy (days), median 3.2 7.1 < 0.05
Antiviral treatment recevied
 48 h after symptom onset, n (%) 154 (55.0%) 1 (7.69%) < 0.01
ICU – intensive care unit; COPD – chronic obstructive pulmonary disease; WBC – white blood cells;
PMN – polymorphonuclears; LYM – lymphocytes; CRP – C reactive proteinVolumen 70, Broj 2 VOJNOSANITETSKI PREGLED Strana 159
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Low blood oxygen saturation (SaO2  92%) was more
common in the patients admitted to an ICU, 10/13 (76.92%),
compared to those who were not, 28/280 (10%), and this dif-
ference was significant (p < 0.01).
Among the evaluated laboratory parameters, serum
CRP levels on admission were the only significantly differ-
entiated factor (p < 0.01) between ICU admitted patients and
those who were not (median 93 mg/L vs 198 mg/L). Serum
CRP levels > 200 mg/L was noticed in 9/13 (69.23%) pa-
tients admitted to an ICU and 85/280 (30.35%) patients who
were not; the difference was also significant (p < 0.05).
Chest radiographic findings consistent with pneumonia
were more prevalent among patients who required ICU care
than among those who did not, but this difference was not
statistically significant (100% vs 68.57%, p > 0.05).
A total of 12/13 (92.3%) patients admitted to an ICU
received antiviral drugs, and all received antibiotics. The
median time from the onset of illness to the initiation of anti-
viral treatment was 7.1 days (range 3–12) for ICU admitted
patients and 3.2 days (range, 1–10) for those not admitted to
ICU (the difference was statistically significant, p < 0.05).
Only one (7.69%) of the ICU patients received antiviral
therapy within 48 h after the onset of symptoms in contrast
to 154/280 (55%) of the non-ICU admitted patients who re-
cevied oseltamivir within 48 h after the onset of symptoms
(the difference was significant, p < 0.01).
Discussion
In the present study, we retrospectively analyzed clini-
cal features, treatment and outcome of 293 patients with con-
firmed or suspected novel influenza A (H1N1) hospitalized
between October 2009 and February 2010. The majority of
the patients (79.3%) were between the age of 10 and 50
years. This is consistent with other studies on 2009 pandemic
influenza which found greater affinity of the novel A (H1N1)
virus for the younger population 
21–27. The median age of the
patients in our study was 32.7 years in contrast to 27 years in
the study of Louie et al. 
28 and 22.6 years in the study of
Xiao et al. 
29. Serologic studies suggest that many older peo-
ple had preexisting antibodies that cross-reacted with the
novel pandemic influenza A (H1N1) 2009 virus. This phe-
nomenon may explain why older people were relatively pro-
tected against contracting the virus, while younger people,
who lacked these antibodies, were more likely infected 
30, 31.
Both genders were equally represented in our study.
The structure of our patients by gender is consistent with the
knowledge of equal sensitivity of both sexes to influenza A
viruses, both seasonal and novel A (H1N1) 
9, Mikiü et al. 
32
found twice as much male patients than female, which is
consistent with the gender predominance of male patients at
the Military Medical Academy in Belgrade.
Infection with pandemic influenza A (H1N1) 2009 vi-
rus causes broad spectrum of clinical syndromes, ranging
from afebrile upper respiratory illness to fulminant viral
pneumonia. Afebrile or atypical presentations of A (H1N1)
infection occurred also in pregnant women, patients with
immunosuppression and other chronic disorders 
33. Most pa-
tients have typical influenza-like illness with fever and cough
that are sometimes accompanied by sore throat and rhinor-
rhea 
2, 24, 33–36. The commonest symptoms in our patients
were: fever (96.24%), cough (81.91%), myalgias (40.61%)
and dyspnea (37.54%). Our results concur with data from the
United States 
6, 13, 14, Mexico 
2 and Shanghai 
29 in which more
than 80% of cases presented with fever. Mild illness without
fever has been reported in 8% to 32% of infected persons 
7, 34.
According to Burke et al. 
37 occurrence of myalgia in addi-
tion to dyspnea, raises high suspicion of A (H1N1) infection.
The incidence of diarrhea in our study (9.22%) was much
lower than previously reported in the United States (25%)
and in the United Kingdom (28%) 
7, 38, 39. In the study of
Liang et al. 
40 fever was reported in 90%, cough in 70%, my-
algia in 30% of patients and none reported diarrhea.
The average time from the onset of illness to hospital
admission in our series of patients was 3.7 days (range from
6 h to 16 days). It was not significantly different in compari-
son to some other studies. In the study of Loui et al. 
28 the
median time from the onset of symptoms to hospitalization
was 2 days (range, 0–31 days),
 in the study of Kumar et al. 
41
4 days (0–18 days)
 and in the study of Jain et al.
 7 it was 3
days (0–18 days).
History of an underlying medical condition was re-
ported in 60%–83% of patients with pandemic influenza
A(H1N1) 
7. The most common comorbid illness in our pa-
tients were asthma and COPD (15.01%) and chronic cardio-
vascular diseases (9.56%), In the study of Bewick et al. 
42
asthma was also the most common comorbid illness (25.2%).
Similarly to our results, chronic cardiovascular disease in the
study of Jain et al. 
7 was seen in 13% of patients and asthma
in 27% of adults patients. Thus, some studies showed that
exacerbation of underlying lung disease appears to be a more
common indication for hospital admission in patients with
seasonal influenza than with pandemic influenza 
21.
A number of studies suggest that certain underlying
chronic medical condition represent risk factors for compli-
cation and severe form of illness. However, in up to 50% of
patients with severe disease, no conventional risk factor
could be identified 
21. In our study, 38.9% of patients had an
underlying medical condition on admission and we also
found no significant difference in the prevalence of back-
ground medical conditions among the patients who required
hospitalization in the ICU and those who did not.
Laboratory findings at presentation, in patients with in-
fluenza include normal or low-normal leukocyte counts with
lymphocytopenia and elevations in the levels of serum ami-
notransferases, lactate dehydrogenase, creatine kinase and
creatinine 
2, 24, 25, 27. Studies have shown that in the early and
late stages of influenza infection, neutrophils play a vital role
in inhibiting viral replication, and an inferior status in neu-
trophil activity may result in severe form of illness even if
the viral strain has only medium virulence 
43, 44. In our study,
22.87% of the patients had leucopenia, 36.86% of them had
lymphopenia and 19.31% had leucocytosis. The number of
patients with leucopenia was similar to that of other authors.
For example, in the study of Jain et al. 
7 20% of patients had
leucopenia and only 18% of patients had leucocytosis. In theStrana 160 VOJNOSANITETSKI PREGLED Volumen 70, Broj 2
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study of Liang et al.
40 leucocytosis was noted in 30%, neu-
trophilia in 40%, lymphopenia in 50% patients while in the
study of Mu et al. 
45 almost 52% of patients had a neutrophil
level higher than the upper normal limit, only 5.4% had ele-
vated lymphocyte level and 32.6% had lymphopenia. The
pandemic influenza A (H1N1) virus also affected hepatic
functioning. This collateral damage to the liver may result
from the viral activation of the Kupfer cells in the liver 
45. In
our study 14% of the patients showed increased levels of se-
rum ALT and 3.41% of the patients had increased GGT. This
is consistent with the study of Mu et al. 
45 who noticed 7.6%
of the patients with increased levels of ALT and 4.9% of the
patients with increased levels of GGT.
The diagnostic utility of biomarkers such as CRP and
procalcitonin may be useful for differentiation between viral
and bacterial mixed infection. Given the tendency to admin-
ister both antiviral and antibacterial therapy to patients in-
fected with novel inflenza A (H1N1) virus, low procalcitonin
and CRP levels when combined with clinical judgement,
may allow earlier cessation of antibiotic therapy 
46. A retro-
spective observational study performed at an Australian hos-
pital conducted by Ingram et al. 
47 suggested a CRP cutoff of
> 200 mg/L best identified patients with bacterial mixed in-
fection (sensitivity 100%, specifity 87.5%). In this study the
median value for CRP in the bacterial mixed infection was
363 mg/L and 103 mg/L in the A (H1N1) group. In our study
92.49% of the patients had increased CRP levels > 5 mg/L
(median 133, range 7–312)  while we noticed CRP levels
> 200 mg/L in 32.08% of patients. Humoral immunity test in
the study of Mu et al. 
45 showed that 71.4% patients had a
CRP level higher than the upper limit of the normal range
(median 10.80 mg/L). In the study of Bewick et al. 
42 median
CRP level was 85 (range 34–199) and in the study of Liang
et al. 
40 it
 was 20 mg/L (range 7–57).
Song et al. 
48 analysed clinical, laboratory and radio-
logic characteristics of pandemic influenza A (H1N1) pneu-
monia and concluded that both procalcitonin and CRP would
be helpful to differentiate primary influenza pneumonia from
concomitant secondary bacterial pneumonia (CRP cutoff
value 86 mg/L, sensitivity 81% and specifity 59% was dis-
criminative between patients with concomitant bacterial
pneumonia and patients with primary influenza pneumonia).
In the study of Ahn et al. 
49 the sensitivity and specifity for
detection of mixed bacterial infection pneumonia during the
pandemic A (H1N1) influenza were 69% and 63% for CRP
levels  >  100  mg/L. The results of the study conducted by
Zimmerman et al. 
50 also confirmed that high serum CRP
levels were associated with a severe course of influenza A
(H1N1) and low initial serum CRP levels were an excellent
predictor of good outcome. None of the patients with CRP
levels lower than 33 mg/L in this study required ICU care.
Radiographic findings of patients with influenza A
(H1N1) virus infection commonly include diffuse mixed in-
terstitial and alveolar infiltrates, particularly in patients with
bacterial coinfection 
7. A principal clinical syndrome leading
to hospitalization and intensive care is diffuse viral pneumo-
nitis associated with severe hypoxemia, ARDS, and some-
times shock and renal failure 
38. This syndrome accounted
for approximately 49% to 72% of ICU admissions 
41, 51. In
our study, 192/280 (68,57%) of nonICU patients and 13/13
(100%) of patients who admitted to ICU had radiological
findings that were consistent with pneumonia. This number
is much higher than in findings of Jain et al. 
7 who reported
40% of patients with pneumonia.
  Similarly to our results,
among hospitalized patients with influenza A (H1N1) pre-
sented by Louie et al. 
28 as many as 66% had pneumonia.
The currently circulating influenza A (H1N1) virus is
susceptible to the neuraminidase inhibitors oseltamivir and
zanamivir. Therapy with a neuraminidase inhibitor is espe-
cially important for patients with risk factors, including
pregnancy and those with severe or progressive clinical ill-
ness. According to the WHO guidelines on the pharmaco-
logic management of influenza virus, patients who are at risk
for pneumonia should be treated with oseltamivir or
zanamivir as soon as symptoms develop 
52–55. Available
findings suggested the importance of early use of antiviral
drugs and antibiotics in the treatment of serious cases 
33, 38.
Previous observational studies showed that oseltamivir
could reduce the duration of symptoms and shorten the dura-
tion of fever in cases of influenza A (H1N1) infection 
21, 28, 29.
Most of our patients (94.88%) were treated with oseltamivir
and 56.61% of the patients received antiviral therapy within
48 h. The fever disappeared in our patients for the mean 2.38
days after the initiation of the therapy. This is consistent with
the data of Hong et al. 
39 who found that the fever disap-
peared for the mean 2.46 days. Totally 85.3% of patients in
this study received oseltamivir within 48 h following the on-
set of symptoms.
Some studies showed that pulmonary complications are
common in patients with influenza A (H1N1) infection ad-
mitted to ICU, which required early antibiotic therapy in
combination with antiviral treatment 
56. In this regard, in
most studies, antibiotic therapy was administered in almost
all hospitalized patients 
7, 32. In a study of Jain et al. 
7 97% of
patients with radiographic findings that were consistent with
pneumonia were treated with antibiotics. Commonly used
antibiotics included ceftriaxone, azithromycin, vancomycin
and levofloxacin. In the study of Falagas et al. 
57 85% of pa-
tients received antibiotics and similarly to this, in our study
antibiotics were given in 93.5% of the patients. Commonly
used antibiotics included ceftriaxone, azithromycin and cip-
rofloxacin. We applied antibiotic treatment in all the patients
with pneumonia and also in the patients with increased CRP
levels because of suspect bacterial mixed infection. Accord-
ing to the literature data, Staphylococcus aureus is an im-
portant cause of secondary bacterial pneumonia with a high
mortality rate and treatment of pneumonia should include
empirical coverage for this pathogen 
24. Influenza A (H1N1)
virus infection can induce rapidly progressive lower respira-
tory tract disease resulting in acute lung injury and acute res-
piratory distress syndrome wich calls for intensive care. Se-
vere cases can occur at patients with extreme ages or with
underlying chronic medical condition but they can also occur
in young and previously healthy people 
58–61.
In pandemic influenza A (HIN1), data suggested that
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clearance and improved survival in hospitalized patients. Un-
fortunately, many patients had a delay before starting antivi-
ral therapy 
21. In the study of Jain et al. 
7 25% of the patients
were admitted to ICU. These patients had longer time be-
tween the onset of illness and the initiations of antiviral ther-
apy (median 6 days), as compared with patients who were
not admitted to ICU (median 3 days). Similarly, in our study
the median time from the onset of illness to the initiation of
antiviral therapy was 7.1 days for patients admitted to ICU
and 3.2 days for non-ICU patients. The small number of pa-
tients (4.44%) admitted to an ICU in our study might be at-
tributed to the early administration antiviral therapy. Totally
55% of patients not admitted to ICU received oseltamivir
within 48 h in contrast to only one of ICU patients who re-
ceived antiviral therapy within 48 h after the onset of symp-
toms. This is consistent with the study of Sertogullarindan et
al. 
60 who found that none of the patients admitted to ICU
had taken oseltamivir within 48 h.
Conclusion
The most novel influenza A (H1N1) 2009 infection pre-
sented the mild respiratory disease. Prompt antiviral therapy
in patients with A (H1N1) virus infection seem to be the best
approach to avoid serious form of disease requiring ICU ad-
mission. Special attention should be paid to patients with low
level of peripheral oxygen saturation and raised CRP serum
level. Early identification of risk patients for developing se-
vere disease is an important aim in preparation for future
waves of pandemic A (H1N1) influenza.
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